Peregrine rises on "robust" Phase IIb second-line NSCLC data
This article was originally published in Scrip
Executive Summary
Peregrine Pharmaceuticals shares rose by as much as 36% in early trading, and closed at $0.53, up by 20.5%, on the back of promising Phase IIb data for its first-in-class phosphatidylserine inhibitor, bavituximab. The study showed that, when used in conjunction with standard chemotherapy docetaxel, it was more active than docetaxel alone in second-line non-small cell cancer (NSCLC) – providing a doubling of objective tumour response and encouraging preliminary survival data in the study.